



PROYECTOS LAB AECC

Adjudicatarios

**Dr. Álvaro Aytes Meneses**

Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona

Dissecting EZH2-SWI/SNF antagonism to target cell plasticity in therapy resistant prostate cancer.

Dr. Asís Palazón

CIC Biogune, Vizcaya

Development of a novel cell therapy platform for the treatment of cancer.

Dr. Carlos Fernández de Larrea

Fundació Privada Clínic per a la Recerca Biomèdica (FCRB), Barcelona

Strategies to overcome antigen escape relapses and improve CAR T-cell persistence in multiple myeloma.

Dra. María de la Fuente Freire

Instituto de Investigación Sanitaria de Santiago (IDIS-CHUS), La Coruña

Development of a first-in-class targeted therapy for metastatic NSCLC.

Dra. Eva María Novoa Pardo

Centro de Regulación Genómica (CRG), Barcelona

Native RNA nanopore sequencing as a novel technology for rapid cancer screening and monitoring.

Dra. Lorea Blázquez

Instituto de Investigación Sanitaria Biodonostia (IIS Biodonostia), Guipúzcoa

Evaluation of CRISPR-dCas13 system as a precision medicine approach for glioblastoma multiforme.

Dra. Verónica Rodilla

Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), Barcelona

Tumor heterogeneity comprehension for an improved diagnosis and treatment choice for breast cancer.



PROYECTOS LAB AECC

Adjudicatarios

**Dr. Matthias Drosten**

Centro de Investigación del Cáncer, CIC-
CSIC, Salamanca

Linking KRAS oncogene signaling and the tumor microenvironment in lung cancer: mechanistic implications and therapeutic opportunities.

Dra. Cristina Mayor Ruiz

Institut de Recerca Biomédica (IRB),
Barcelona

Modulating our ubiquitination machinery to innovate treatments and drug discovery in cancer.

Dra. Biola M. Javierre

Institut de Recerca Contra la Leucèmia
Josep Carreras (IJC), Barcelona

Multi-omics approach to improve therapeutic management of T-cell acute lymphoblastic leukemia.

Dra. Melissa García

Universidad de Málaga, Málaga

Targeting the non tumor players of the tumor microenvironment to improve the efficacy of the current therapies and prevent metastasis.

Dr. Miguel Fernández de Sanmamed

Clínica Universidad de Navarra, Navarra

IL-8/CXCR pathway modulation plus CD137 co-stimulation as a way to overcome resistance to PD-1/PD-L1 pathway blockade in melanoma and kidney cancer patients.

Dra. Verónica Torrano Moya

Universidad del País Vasco (UPV/EHU),
Vizcaya

Unravel the therapeutic potential of targeting cell communication in aggressive prostate cancer.